Skip to main content
Top
Published in:

Open Access 01-12-2024 | Research

“If they take it without knowing, they will default…”: perceptions of targeted information transfer to promote adherence to intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy in western Kenya

Authors: Jenna Hoyt, Hellen C. Barsosio, Isdorah A. Odero, Benson Omondi, Florence Achieng, Simon Kariuki, Jenny Hill, Jayne Webster

Published in: Malaria Journal | Issue 1/2024

Login to get access

Abstract

Background

Increasing resistance to sulfadoxine-pyrimethamine (SP) threatens the effectiveness of intermittent preventive treatment (IPTp) to prevent malaria in pregnancy. Dihydroartemisinin-piperaquine (DP) is the most promising candidate to emerge from clinical trials, but requires a multi-day regimen. Despite being a single-dose regimen, coverage of IPTp-SP remains low, fuelling concerns about adherence to multi-day drug options. An implementation feasibility trial in routine antenatal care settings in western Kenya demonstrated that adherence to the multi-day DP regimen was improved when IPTp-DP was delivered with a targeted information transfer intervention that comprised healthcare provider training and communication tools to support delivery and uptake. This study explored healthcare provider and pregnant women perspectives to understand (1) how the targeted information transfer improved adherence to IPTp-DP and (2) if improved adherence to IPTp-DP influenced provider perceptions towards implementation feasibility of multi-day drug regimens for IPTp.

Methods

In-depth interviews were conducted with 64 healthcare providers and 64 pregnant women, selected using a convenience sampling approach from across the three trial arms: IPTp-DP+ (with intervention), IPTp-DP, and current standard of care IPTp-SP. Transcripts from healthcare providers and pregnant women were coded in Nvivo-12 using separate a priori frameworks that included components of the consolidated framework for implementation research. Thematic analysis was used to understand how the targeted information transfer affected adherence to IPTp-DP and how concerns about adherence might influence provider perceptions towards multi-day drug regimens for IPTp.

Results

Adherence to IPTp-DP doses taken at home was compromised when women experienced unpleasant side effects. Pregnant women valued being given information about IPTp-DP, including potential side effects and how to manage them. Among providers in the IPTp-DP + arm, confidence in advising women on how to manage side effects increased, and they believed this guidance improved adherence. When concerns about adherence were reduced, providers in the IPTp-DP + arm were positive about implementation feasibility, whereas providers in the IPTp-SP arm remained focused on the dosing complexities and were less convinced of the feasibility of implementing IPTp-DP.

Conclusions

Healthcare provider confidence in advising women on how to minimize side effects was boosted through targeted information transfer, which was perceived to improve adherence to IPTp-DP. Policy makers are encouraged to consider supportive interventions that enhance provider confidence around adherence should they shift to multi-day drug regimens for IPTp.
Appendix
Available only for authorised users
Literature
1.
go back to reference Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.CrossRefPubMed Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.CrossRefPubMed
2.
go back to reference Steketee RW, Nahlen BL, Parise ME, Menéndez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64(Suppl 1–2):28–35.CrossRefPubMed Steketee RW, Nahlen BL, Parise ME, Menéndez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64(Suppl 1–2):28–35.CrossRefPubMed
3.
go back to reference WHO. Guidelines for malaria – 31 March 2021. Geneva; World Health Organization; 2022. WHO. Guidelines for malaria – 31 March 2021. Geneva; World Health Organization; 2022.
4.
go back to reference Ministry of Health Kenya. Ministry of Public Health and Sanitation. The Kenya Malaria Strategy 2009–2018 (Revised 2014). 2014. Ministry of Health Kenya. Ministry of Public Health and Sanitation. The Kenya Malaria Strategy 2009–2018 (Revised 2014). 2014.
5.
go back to reference Amimo F, Lambert B, Magit A, Sacarlal J, Hashizume M, Shibuya K. Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends. BMJ Glob Health. 2020;5:e003217.CrossRefPubMedPubMedCentral Amimo F, Lambert B, Magit A, Sacarlal J, Hashizume M, Shibuya K. Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends. BMJ Glob Health. 2020;5:e003217.CrossRefPubMedPubMedCentral
6.
go back to reference Kajubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, et al. Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. Lancet. 2019;393:1428–39.CrossRefPubMed Kajubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, et al. Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. Lancet. 2019;393:1428–39.CrossRefPubMed
7.
go back to reference Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, et al. Dihydroartemisinin–piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016;374:928–39.CrossRefPubMedPubMedCentral Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, et al. Dihydroartemisinin–piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016;374:928–39.CrossRefPubMedPubMedCentral
8.
go back to reference Rogerson SJ, Desai M, Mayor A, Sicuri E, Taylor SM, van Eijk AM. Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem. Lancet Infect Dis. 2018;18:e107–18.CrossRefPubMed Rogerson SJ, Desai M, Mayor A, Sicuri E, Taylor SM, van Eijk AM. Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem. Lancet Infect Dis. 2018;18:e107–18.CrossRefPubMed
9.
go back to reference Madanitsa M, Barsosio HC, Minja DTR, Mtove G, Kavishe RA, Dodd J, et al. Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled Tr. Lancet. 2023;401:1020–36.CrossRefPubMedPubMedCentral Madanitsa M, Barsosio HC, Minja DTR, Mtove G, Kavishe RA, Dodd J, et al. Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquine with and without azithromycin versus monthly sulfadoxine–pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled Tr. Lancet. 2023;401:1020–36.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Hill J, Hoyt J, Achieng F, Ouma P, L’lanziva A, Kariuki S, et al. User and provider acceptability of intermittent screening and treatment and intermittent preventive treatment with dihydroartemisinin-piperaquine to prevent malaria in pregnancy in western Kenya. PLoS ONE. 2016;11:e0150259.CrossRefPubMedPubMedCentral Hill J, Hoyt J, Achieng F, Ouma P, L’lanziva A, Kariuki S, et al. User and provider acceptability of intermittent screening and treatment and intermittent preventive treatment with dihydroartemisinin-piperaquine to prevent malaria in pregnancy in western Kenya. PLoS ONE. 2016;11:e0150259.CrossRefPubMedPubMedCentral
12.
go back to reference Hoyt J, Hill J, Achieng F, Ouma P, Kariuki S, Desai M, et al. Healthcare provider and pregnant women’s perspectives on the implementation of intermittent screening and treatment with dihydroartemisinin–piperaquine for malaria in pregnancy in western Kenya: a qualitative study. Malar J. 2021;20:291.CrossRefPubMedPubMedCentral Hoyt J, Hill J, Achieng F, Ouma P, Kariuki S, Desai M, et al. Healthcare provider and pregnant women’s perspectives on the implementation of intermittent screening and treatment with dihydroartemisinin–piperaquine for malaria in pregnancy in western Kenya: a qualitative study. Malar J. 2021;20:291.CrossRefPubMedPubMedCentral
13.
go back to reference Almond D, Madanitsa M, Mwapasa V, Kalilani-Phiri L, Webster J, Ter Kuile F, et al. Provider and user acceptability of intermittent screening and treatment for the control of malaria in pregnancy in Malawi. Malar J. 2016;15:574.CrossRefPubMedPubMedCentral Almond D, Madanitsa M, Mwapasa V, Kalilani-Phiri L, Webster J, Ter Kuile F, et al. Provider and user acceptability of intermittent screening and treatment for the control of malaria in pregnancy in Malawi. Malar J. 2016;15:574.CrossRefPubMedPubMedCentral
14.
go back to reference Hill J, Ouma P, Oluoch S, Bruce J, Kariuki S, Desai M, et al. Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya. Malar J. 2020;19:433.CrossRefPubMedPubMedCentral Hill J, Ouma P, Oluoch S, Bruce J, Kariuki S, Desai M, et al. Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya. Malar J. 2020;19:433.CrossRefPubMedPubMedCentral
15.
go back to reference Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatmen of malaria: a systematic review of the evidence. Malar J. 2014;13:7.CrossRefPubMedPubMedCentral Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatmen of malaria: a systematic review of the evidence. Malar J. 2014;13:7.CrossRefPubMedPubMedCentral
16.
go back to reference MacE KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, et al. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in Rural Malawi. Clin Infect Dis. 2011;53:772–9.CrossRefPubMed MacE KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, et al. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in Rural Malawi. Clin Infect Dis. 2011;53:772–9.CrossRefPubMed
17.
go back to reference Swain TR, Raulo A, Mohapatra N, Singha MR. Information education and communication can improve adherence to artemether-lumefantrine combination in patients of uncomplicated falciparum malaria. J Clin Diagn Res. 2015;9:FC01–3.PubMedPubMedCentral Swain TR, Raulo A, Mohapatra N, Singha MR. Information education and communication can improve adherence to artemether-lumefantrine combination in patients of uncomplicated falciparum malaria. J Clin Diagn Res. 2015;9:FC01–3.PubMedPubMedCentral
18.
go back to reference Hill J, Hoyt J, van Eijk AM, D’Mello-Guyett L, ter Kuile FO, Steketee R, et al. Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-saharan Africa: a systematic review and meta-analysis. PLoS Med. 2013;10:e1001488.CrossRefPubMedPubMedCentral Hill J, Hoyt J, van Eijk AM, D’Mello-Guyett L, ter Kuile FO, Steketee R, et al. Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-saharan Africa: a systematic review and meta-analysis. PLoS Med. 2013;10:e1001488.CrossRefPubMedPubMedCentral
19.
go back to reference Rassi C, Graham K, King R, Ssekitooleko J, Mufubenga P, Gudoi SS. Assessing demand-side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative study in two regions of Uganda. Malar J. 2016;15:530.CrossRefPubMedPubMedCentral Rassi C, Graham K, King R, Ssekitooleko J, Mufubenga P, Gudoi SS. Assessing demand-side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative study in two regions of Uganda. Malar J. 2016;15:530.CrossRefPubMedPubMedCentral
20.
go back to reference Barsosio HC, Webster J, Omiti F, K’Oloo A, Odero IA, Ojuok MA, et al. Delivery effectiveness of and adherence to intermittent preventive treatment for malaria in pregnancy with dihydroartemisinin–piperaquine with or without targeted information transfer or sulfadoxine–pyrimethamine in western Kenya: a three-armed, pragmatic, open-label, cluster-randomised trial. Lancet Glob Health. 2024;12:e1660–72.CrossRefPubMed Barsosio HC, Webster J, Omiti F, K’Oloo A, Odero IA, Ojuok MA, et al. Delivery effectiveness of and adherence to intermittent preventive treatment for malaria in pregnancy with dihydroartemisinin–piperaquine with or without targeted information transfer or sulfadoxine–pyrimethamine in western Kenya: a three-armed, pragmatic, open-label, cluster-randomised trial. Lancet Glob Health. 2024;12:e1660–72.CrossRefPubMed
21.
go back to reference Division of National Malaria Programme (DNMP), ICF. Kenya Malaria Indicator Survey 2020. Nairobi, Kenya and Rockville, Maryland USA; 2021. Division of National Malaria Programme (DNMP), ICF. Kenya Malaria Indicator Survey 2020. Nairobi, Kenya and Rockville, Maryland USA; 2021.
22.
go back to reference Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the consolidated framework for implementation research (CFIR). Implement Sci. 2013;8:51.CrossRefPubMedPubMedCentral Damschroder LJ, Lowery JC. Evaluation of a large-scale weight management program using the consolidated framework for implementation research (CFIR). Implement Sci. 2013;8:51.CrossRefPubMedPubMedCentral
23.
24.
go back to reference Pell C, Meñaca A, Were F, Afrah NA, Chatio S, Manda-Taylor L, et al. Factors affecting antenatal care attendance: results from qualitative studies in Ghana, Kenya and Malawi. PLoS ONE. 2013;8:e53747.CrossRefPubMedPubMedCentral Pell C, Meñaca A, Were F, Afrah NA, Chatio S, Manda-Taylor L, et al. Factors affecting antenatal care attendance: results from qualitative studies in Ghana, Kenya and Malawi. PLoS ONE. 2013;8:e53747.CrossRefPubMedPubMedCentral
25.
go back to reference Exavery A, Mbaruku G, Mbuyita S, Makemba A, Kinyonge IP, Kweka H. Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania. Malar J. 2014;13:22.CrossRefPubMedPubMedCentral Exavery A, Mbaruku G, Mbuyita S, Makemba A, Kinyonge IP, Kweka H. Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania. Malar J. 2014;13:22.CrossRefPubMedPubMedCentral
26.
go back to reference Aberese-Ako M, Magnussen P, Ampofo GD, Gyapong M, Ansah E, Tagbor H. An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context. PLoS ONE. 2021;16:e0257666.CrossRefPubMedPubMedCentral Aberese-Ako M, Magnussen P, Ampofo GD, Gyapong M, Ansah E, Tagbor H. An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context. PLoS ONE. 2021;16:e0257666.CrossRefPubMedPubMedCentral
27.
go back to reference Searle AR, Hurley EA, Doumbia SO, Winch PJ. They merely prescribe and i merely swallow: perceptions of antenatal pharmaceuticals and nutritional supplements among pregnant women in bamako, Mali. Matern Child Health J. 2020;24:110–20.CrossRefPubMed Searle AR, Hurley EA, Doumbia SO, Winch PJ. They merely prescribe and i merely swallow: perceptions of antenatal pharmaceuticals and nutritional supplements among pregnant women in bamako, Mali. Matern Child Health J. 2020;24:110–20.CrossRefPubMed
28.
go back to reference Johnson MO, Neilands TB, Dilworth S, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV treatment self-efficacy scale (HIV-ASES). J Behav Med. 2007;30:83–91.CrossRef Johnson MO, Neilands TB, Dilworth S, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV treatment self-efficacy scale (HIV-ASES). J Behav Med. 2007;30:83–91.CrossRef
29.
go back to reference Zhang L, Li X, Lin Z, Jacques-Tiura AJ, Xu J, Zhou Y, et al. Side effects, adherence self-efficacy, and adherence to antiretroviral treatment (ART): a mediation analysis in a Chinese sample. AIDS Care. 2016;28:919–26.CrossRefPubMedPubMedCentral Zhang L, Li X, Lin Z, Jacques-Tiura AJ, Xu J, Zhou Y, et al. Side effects, adherence self-efficacy, and adherence to antiretroviral treatment (ART): a mediation analysis in a Chinese sample. AIDS Care. 2016;28:919–26.CrossRefPubMedPubMedCentral
30.
go back to reference Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17:88.CrossRefPubMedPubMedCentral Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17:88.CrossRefPubMedPubMedCentral
Metadata
Title
“If they take it without knowing, they will default…”: perceptions of targeted information transfer to promote adherence to intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy in western Kenya
Authors
Jenna Hoyt
Hellen C. Barsosio
Isdorah A. Odero
Benson Omondi
Florence Achieng
Simon Kariuki
Jenny Hill
Jayne Webster
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2024
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-024-05131-6

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more